ERBB2 and Hepatitis: The KEYNOTE-028 study, which investigated pembrolizumab monotherapy in patients with estrogen receptor (ER)+, HER2− MBC, reported no transaminase elevations; however, one grade 3 hepatitis event was reported (4%).